Hjem › Diffust stort B-celle lymfom › Texas › Houston
Diffust stort B-celle lymfom kliniske forsøg i Houston, TX
17 studier for Diffust stort B-celle lymfom søger deltagere på steder i og omkring Houston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruttererFase 2
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservationsstudie
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RekruttererFase 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruttererFase 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekruttererFase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruttererFase 1
- Md Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekruttererFase 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruttererFase 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RekruttererFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RekruttererFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RekruttererFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
RekruttererFase 1
- MD Anderson Cancer Center, Houston
Diffust stort B-celle lymfom forsøg i andre byer
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Los Angeles, CA17 studier
- Boston, MA16 studier
- Milwaukee, WI16 studier
- Portland, OR15 studier
- Nashville, TN15 studier
- Philadelphia, PA15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
Andre studier i Houston
- Ikke-småcellet lungecancer145 studier
- Brystkræft126 studier
- Kræft (alle typer)121 studier
- Metastatisk cancer104 studier
- Colorektal kræft102 studier
- Ægstockræft89 studier
- Akut myeloid leukæmi85 studier
- Lungecancer78 studier
- Prostatakræft76 studier
- Livmoderslimhindekræft68 studier
- Bugspytkirtelkræft61 studier
- Melanom59 studier
Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.